Institutional Investors Lead Shift in Advaxis Inc (NASDAQ:ADXS) Sentiment

April 22, 2018 - By Winifred Garcia

Advaxis, Inc. (NASDAQ:ADXS) Logo

Sentiment for Advaxis Inc (NASDAQ:ADXS)

Advaxis Inc (NASDAQ:ADXS) institutional sentiment decreased to 1.12 in Q4 2017. Its down -0.11, from 1.23 in 2017Q3. The ratio has worsened, as 38 investment managers opened new and increased stock positions, while 34 trimmed and sold holdings in Advaxis Inc. The investment managers in our partner’s database reported: 15.17 million shares, down from 16.94 million shares in 2017Q3. Also, the number of investment managers holding Advaxis Inc in their top 10 stock positions decreased from 1 to 0 for a decrease of 1. Sold All: 17 Reduced: 17 Increased: 22 New Position: 16.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $85.80 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

The stock decreased 2.96% or $0.05 during the last trading session, reaching $1.64. About 315,495 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has declined 77.70% since April 22, 2017 and is downtrending. It has underperformed by 89.25% the S&P500.

Analysts await Advaxis, Inc. (NASDAQ:ADXS) to report earnings on June, 5. They expect $-0.41 EPS, up 19.61 % or $0.10 from last year’s $-0.51 per share. After $-0.49 actual EPS reported by Advaxis, Inc. for the previous quarter, Wall Street now forecasts -16.33 % EPS growth.

Dafna Capital Management Llc holds 0.38% of its portfolio in Advaxis, Inc. for 247,000 shares. Cutler Capital Management Llc owns 75,876 shares or 0.09% of their US portfolio. Moreover, Franklin Street Advisors Inc Nc has 0.06% invested in the company for 129,800 shares. The California-based Stonebridge Capital Management Inc has invested 0.04% in the stock. Adage Capital Partners Gp L.L.C., a Massachusetts-based fund reported 4.00 million shares.

Since January 1, 0001, it had 0 insider purchases, and 3 selling transactions for $20,259 activity.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Ratings analysis reveals 100% of Advaxis’s analysts are positive. Out of 2 Wall Street analysts rating Advaxis, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5 while the high is $23.0. The stock’s average target of $5.50 is 235.37% above today’s ($1.64) share price. ADXS was included in 4 notes of analysts from November 8, 2017. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, December 27. The stock has “Buy” rating by H.C. Wainwright on Wednesday, March 14. The firm earned “Overweight” rating on Tuesday, March 13 by Cantor Fitzgerald. H.C. Wainwright maintained it with “Buy” rating and $23.0 target in Wednesday, November 8 report.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.